Opinion|Videos|May 2, 2025
Balancing Survival and Quality of Life in 1L EGFRm NSCLC Treatment Decisions
Panelists discuss how treatment choice involves weighing quality of life against treatment burden, considering factors such as hospital visits for infusions vs oral medications at home.
Advertisement
Episodes in this series
Quality of Life vs Treatment Burden
Main Discussion Topics:
- Impact of different treatment regimens on patient quality of life
- Comparison of treatment burdens: oral therapy vs infusion-based regimens
- Consideration of financial costs and logistical challenges associated with different treatments
Key Points for Physicians:
- Treatment burden varies significantly: osimertinib is a daily pill with visits every 3 months, whereas combination therapies require infusions every 2 to 3 weeks
- More-intensive regimens involve greater “medicalization” of patient care
- Financial and logistical costs (travel, parking, childcare) must be considered
Notable Insights:
Patients fall on different ends of the spectrum regarding treatment preferences—some prioritize efficacy regardless of burden, and others prefer less- intensive regimens to maintain quality of life.
Clinical Significance:
The treatment decision ultimately depends on aligning therapy choice with individual patient values, circumstances, and priorities related to efficacy, quality of life, and treatment burden.
Advertisement
Related to this article
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5